Medtronic (NYSE:MDT) said today that the FDA approved its InterStim smart programmer, designed to work with the company’s InterStim sacral neurmodulation system intended for tor treating overactive bladder, chronic fecal incontinence and non-obstructive urinary retention.
The newly cleared smart programmer is run on a Samsung Electronics (LON:BC94) mobile device and allows clinicians to personalize patient care and manage therapy from a single access point, the Fridley, Minn.-based medical giant said.
“The incorporation of consumer technology in medical device solutions, such as the InterStim system, is not only helping patients integrate these solutions into their daily lives, it’s also empowering clinicians to evolve and digitally transform their practice. Medtronic continues to lead the market in these types of healthcare innovations, and we are proud to partner with them to bring these important solutions to patients and clinicians,” Samsung Electronics America chief medical officer Dr. David Rhew said in a press release.
Medtronic’s InterStim programmer uses an app-based platform that allows for implant and long-term therapy management, allowing physicians to check magnetic resonance imaging eligibility and access to detailed views of a patient’s therapy experience, the company said.
“Medtronic pioneered sacral neuromodulation two decades ago and we continue to innovate to improve the patient and physician experience and make it easier for more patients to find effective relief from both OAB and FI with the InterStim system. The advanced technology of the smart programmer paves the way for future digital health solutions, like digital symptom tracking, and should give physicians and patients confidence that relief and restored quality of life are possible,” Medtronic pelvic health & gastric therapies biz GM Linnea Burman said in a prepared statement.
Earlier this month, Medtronic said that it released a software update for its Puritan Bennet 980 ventilators in a field action labeled by the FDA as Class I.